Growth Hormone Peptide Timing: Why Night Dosing (2026)
The clock on your GH peptide protocol isn’t arbitrary — it’s set by a pulse that fires the moment you fall asleep.
Abstract: Growth hormone peptide timing is the single highest-leverage variable in any GH-secretagogue protocol, and almost every credible source lands on the same answer: dose at night, right before sleep, on an empty stomach. This guide explains the physiology behind that rule — the deep-sleep GH pulse, the somatostatin “brake,” and the food effect — then covers the 30–45-minute window that actually matters, the long-acting and oral exceptions where the rule changes, and why secretagogue timing is a different question from injecting recombinant HGH.
If you have read a protocol for sermorelin, CJC-1295, or ipamorelin, you have seen the instruction: inject before bed, on an empty stomach. Growth hormone peptide timing is treated as a footnote, but it is closer to the whole game. A GH secretagogue does not deliver growth hormone — it asks your pituitary to release more of its own. How much it releases depends almost entirely on when you ask. Get the timing right and you stack the peptide’s pulse on top of your body’s single largest natural one. Get it wrong and you are fighting your own physiology.
This is an explainer, not a dosing directive. The doses below are the ranges reported in research and physician-style sources, and they are labeled as such. The point here is the timing logic — the part competitors state as a rule without ever explaining why.
The growth-hormone pulse that owns the night
Growth hormone (GH) is not secreted at a steady drip. It is pulsatile: the pituitary fires it in discrete bursts, with long, near-empty troughs in between. Across 24 hours, the great majority of total GH output arrives in these pulses rather than in the baseline between them.
The largest pulse of the entire day is the one that fires shortly after you fall asleep. This has been known since 1968, when Takahashi, Kipnis, and Daughaday catheterized eight young adults and drew blood every 30 minutes across 38 nights. In seven of the eight, a large plasma GH peak lasting 1.5–3.5 hours appeared with the onset of deep sleep. Two details from that study are the foundation of everything in this article. First, the peak was delayed when sleep onset was delayed — the pulse tracks when you fall asleep, not the wall clock. Second, subjects who were woken for a few hours and then allowed back to sleep produced another GH peak (Takahashi et al., 1968, PMID 5675428). Sleep, specifically the descent into deep sleep, is the trigger.
Later work tied the pulse to a particular sleep stage. In a review of the field, Van Cauter and Plat reported that in men roughly 70% of GH pulses during sleep coincide with slow-wave (deep) sleep, and the amount of GH released tracks the amount of slow-wave sleep happening at the time (Van Cauter & Plat, 1996, PMID 8627466). The takeaway is blunt: the biggest GH event of your day is welded to your first deep-sleep cycle.
One more fact sets up the timing rationale. With age, the frequency of GH pulses and the baseline between them stay roughly the same — what falls is the amplitude of each pulse. So the physiologic goal of a GH peptide is to restore pulse height, layered onto the body’s own rhythm, not to flood the system with a flat, constant level. That is the same principle behind why GH peptides are stacked as a GHRH plus a GHRP — and it is exactly why timing the dose to the natural pulse matters so much.
Why night, specifically: three reasons that compound
Dosing at night is not a tradition. Three independent mechanisms all point to the same window.
1. Somatostatin — the brake — is lowest at night. The GH axis has two accelerators (GHRH and ghrelin/GHRP signaling) and one brake: somatostatin, the hormone that shuts GH release off. Somatostatin tone is at its daily low point overnight, which is precisely what permits the big sleep pulse to happen. Dose a GHRH-type peptide when the brake is already released and the same dose produces a bigger pulse. Dose it during the day, when somatostatin is higher, and the brake fights you.
2. You get to ride the body’s own largest pulse. A well-timed peptide pulse does not replace the nocturnal surge — it adds to it. Stacking an exogenous pulse on top of the endogenous deep-sleep pulse is how you get the largest total GH release of the day, which is why every consumer protocol converges on “before bed.”
3. Night dosing causes less receptor desensitization and can support sleep itself. Repeated daytime stimulation of the GH-secretagogue receptor is more prone to blunting the response over time; aligning the dose with the natural nocturnal pulse is gentler on receptor sensitivity. There is also a feedback loop worth naming: GH secretion and slow-wave sleep reinforce each other, so a dose that respects the deep-sleep window tends to work with sleep architecture rather than against it.
Why the empty stomach matters as much as the clock
“Before bed, on an empty stomach” is really two instructions, and the second is not optional fine print.
Eating raises somatostatin — the brake — within a couple of hours, with fat being a particularly strong trigger. A meal also drives an insulin response, and elevated insulin/glucose independently suppresses GH release. The practical consequence reported across physician-style and educational sources is large: eating shortly before a GHRH-type dose can blunt the resulting GH pulse by well over half. The working guidance that follows is to keep roughly 3–4 hours clear of food before the dose (especially fatty meals) and to avoid eating for a window afterward, so the pulse can complete before the next insulin spike. (The specific “~60% blunting” figure here comes from educational study-synthesis rather than a single controlled trial; the direction — food meaningfully suppresses the GH response — is standard endocrinology and is echoed by every reputable protocol.)
This is why the empty-stomach rule and the night rule are the same rule wearing two hats: late evening, several hours after dinner, is the one time most people are naturally fasted and dropping into deep sleep with somatostatin at its nadir. The window picks itself.
Growth hormone peptide timing in practice: the 30–45-minute window
Here is the part most guides skip — the actual arithmetic of “before bed.”
After a subcutaneous injection, a short-acting GHRH (sermorelin, CJC-1295 without DAC) plus a GHRP (ipamorelin) produces a GH pulse that peaks roughly 30–45 minutes later, then falls back toward baseline. Deep sleep, meanwhile, typically begins 30–90 minutes after you fall asleep. The goal is to make those two curves overlap: the induced pulse should land as you enter your first slow-wave cycle.
In practice that means injecting as the last thing before sleep — or, if you track your sleep and know when your deep-sleep onset usually lands, about 30–45 minutes ahead of it. The base and the add-on are drawn and injected together so both pituitary receptors fire at once; that simultaneous firing is the entire basis of the GHRH + GHRP synergy. Splitting them defeats the point.
A note on returning to baseline: the value of a short-acting pulse is that it ends. The trough after the pulse is when the body shifts out of growth signaling and into repair and cleanup pathways. A correctly timed nightly pulse restores amplitude and then lets the system fall back — mimicking a younger GH axis instead of overriding it.
The exceptions: long-acting and oral compounds rewrite the rule
“Dose at night” is correct for the short-acting peptides — but not every GH compound is short-acting, and lumping them together is the most common mistake on the SERP.
Long-acting CJC-1295 with DAC is engineered to stay in circulation for days, raising the GH trough (roughly several-fold) rather than producing a clean nightly pulse. Its long half-life means clock timing matters far less — but so does its physiologic logic, because it flattens the very pulsatility you are trying to restore. Oral MK-677 (ibutamoren) is similar in spirit: a once-daily capsule that elevates baseline GH/IGF-1 around the clock rather than sculpting a pulse, and it is usually taken at night more for its sleep and tolerability profile than to hit a 30-minute window. We compare these head-to-head in CJC-1295 DAC vs no-DAC and MK-677 vs CJC-1295: the flat-curve problem. The short version: the more “flat-curve” the compound, the less night timing buys you — and the more you should question whether a flat curve is what you want at all.
What about a second daily dose? For the short-acting pairings, the nightly dose is the priority, and a second dose is realistically only worth considering for a CJC-1295 (no DAC) + ipamorelin protocol — not for sermorelin or tesamorelin alone. When a second dose is used, the reported best slots are around a fasted morning workout or late morning after a multi-hour fast, exploiting the natural daytime mini-pulses and the exercise-driven pulse. A third daily dose is not supported — in one small dataset a second daytime dose failed to produce a measurable pulse in most subjects, and stacking more doses mostly invites desensitization. For most people, one well-timed nightly dose is the whole protocol.
Secretagogue timing vs. injecting actual HGH
A frequent confusion: “if GH peptides go at night, shouldn’t recombinant HGH go at night too?” Not necessarily — and the difference is instructive.
A secretagogue amplifies your own pulse, so you time it to ride the endogenous nocturnal surge. Injecting recombinant HGH (rhGH) is a different mechanism: it delivers exogenous hormone directly rather than coaxing the pituitary, so its optimal timing is its own actively studied question. A 2025 crossover trial found that morning and evening rhGH injections produced comparable effects on growth and IGF-1, but that evening dosing better imitated the body’s natural diurnal GH pattern and its interaction with sleep (Levshtein et al., 2025, PMID 40034226). The lesson is not to copy a rule blindly across categories: the secretagogue “night dose” logic is specifically about augmenting your own deep-sleep pulse. If you are weighing the two approaches, HGH peptide therapy vs. secretagogues lays out the broader tradeoff.
Timing is necessary, not sufficient — what to watch
Perfect timing does not make GH peptides risk-free, and more GH is not automatically better. Both too-low and too-high GH/IGF-1 track higher all-cause mortality (a U-shaped curve), and elevated IGF-1 can feed an existing cancer — the aim is to augment the natural pulse, not to maximize output. Driving GH/IGF-1 up can also worsen insulin sensitivity, which is why serious protocols monitor IGF-1, fasting glucose, and HbA1c alongside lipids. The honest framing of those risks lives in the peptide side-effects and safety guide. Timing optimizes a tool that still has to be used carefully.
The product side simply follows the physiology. A GHRH base — sermorelin (the gentle starter), tesamorelin (the most-studied), or CJC-1295 without DAC (cost-effective but with little human data) — is paired with the selective GHRP ipamorelin and injected together at night, fasted. Pre-mixed forms like CJC-1295 (no DAC) + ipamorelin and ipamorelin + tesamorelin exist precisely so the base and add-on fire on the same schedule. Choosing among the bases is its own decision, covered in how to choose a growth hormone peptide.
Frequently asked questions
When is the best time to take GH peptides? For short-acting secretagogues (sermorelin, CJC-1295 without DAC, ipamorelin), the reported best time is at night, right before sleep, on an empty stomach. That window aligns the peptide-induced pulse with the body’s largest natural GH pulse — the one that fires as you enter deep sleep — when somatostatin (the brake) is at its lowest.
Why does it have to be on an empty stomach? Food, especially fat, raises somatostatin and triggers an insulin response, and both suppress GH release. Eating shortly before a dose can blunt the GH pulse substantially. The common guidance is to stay roughly 3–4 hours clear of food before the dose and avoid eating immediately after.
How long before bed should I inject? A subcutaneous GHRH + GHRP pulse peaks about 30–45 minutes after injection, and deep sleep usually begins 30–90 minutes after falling asleep. Injecting as the last thing before bed (or ~30–45 minutes before your usual deep-sleep onset) overlaps the two. This describes what research and protocols report; it is not a personal dosing instruction.
Does timing matter for CJC-1295 with DAC or MK-677? Much less. Long-acting CJC-1295 with DAC and oral MK-677 raise GH/IGF-1 around the clock rather than producing a discrete pulse, so precise night timing buys little — though it also means they flatten the pulsatility short-acting peptides aim to restore.
Can I take a second dose during the day? For short-acting pairings the nightly dose is the priority. A second daytime dose is realistically only relevant for CJC-1295 (no DAC) + ipamorelin, ideally around a fasted morning workout. A third dose is not supported by the available data.
What if I miss the window and eat late? The dose simply works less well that night because food blunts the pulse — it is not dangerous, just suboptimal. Most sources favor skipping or delaying until adequately fasted rather than dosing right after a meal.
References
- Takahashi, Y., Kipnis, D.M. & Daughaday, W.H. (1968). Growth hormone secretion during sleep. J Clin Invest, 47(9), 2079-2090. PMID 5675428 · DOI 10.1172/JCI105893
- Van Cauter, E. & Plat, L. (1996). Physiology of growth hormone secretion during sleep. J Pediatr, 128(5 Pt 2), S32-S37. PMID 8627466 · DOI 10.1016/S0022-3476(96)70008-2
- Veldhuis, J.D. et al. (2012). Pulsatile Growth Hormone Secretion: Clinical Applications. Endocrine Reviews.
- Levshtein, A., Sharkia, M., Shimshi-Barash, M., Almagor, T., Albertsson-Wikland, K., Hochberg, Z., Pillar, G. & German, A. (2025). Morning vs. evening growth hormone injections and their impact on sleep-wake patterns and daytime alertness. Front Endocrinol, 16, 1483199. PMID 40034226 · DOI 10.3389/fendo.2025.1483199
Provenance note: the deep-sleep GH pulse, its dependence on sleep onset, and its slow-wave-sleep coupling are clinical/human findings (Takahashi 1968; Van Cauter & Plat 1996). The somatostatin-nadir and desensitization rationale, the ~30–45-minute pulse-peak and ~60% food-blunting figures, and the second-dose timing come from physician and educational study-syntheses and are labeled as such in the text.
*Research and educational use only. This article describes what has been observed or reported in research and does not constitute medical advice, a treatment recommendation, or a